Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver

Diabetic Medicine

Volumn 29, Issue 2, 2012, Pages 220-226

  Targher, G ^a   Pichiri, I ^a   Zoppini, G ^a   Trombetta, M ^a   Bonora, E ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Chronic kidney disease; Liver fat; Metabolic syndrome; Non alcoholic fatty liver; Type 1 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; ECHOGRAPHY; FAMILY HISTORY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; FATTY LIVER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ITALY; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 84855812468     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03427.x     Document Type: Article

References (32)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17: 863-869.
2. de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48: S104-S112.
3. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008; 93: S74-S80.
4. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
6. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011; 56: 35-45.
7. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010; 20: 583-590.
8. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5: 2166-2171.
9. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40: 437-442.
10. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.
11. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Gamma-glutamyltransferase as a predictor of chronic kidney disease in non-hypertensive and non-diabetic Korean men. Clin Chem 2007; 53: 71-77.
12. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K et al. Non-alcoholic fatty liver disease predicts chronic kidney disease in non-hypertensive and non-diabetic Korean men. Metabolism 2008; 57: 569-576.
13. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19: 1564-1570.
14. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010; 53: 1341-1348.
15. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298: 2038-2047.
16. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
17. Williams GD, Proudfit AH, Quinn EA, Campbell KE. Variation in quantity-frequency measures of alcohol consumption from a general population survey. Workshop on measurement issues in alcohol consumption. Addiction 1994; 89: 413-420.
18. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003; 6: 407-413.
19. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
20. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR et al.; 4S Group and the AFCAPS/TexCAPS Research Group The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
21. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
22. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011; 34: S11-S61.
23. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14: 3476-3483.
24. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998; 21: 610-614.
25. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: 'double diabetes' in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707-712.
26. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M et al. FinnDiane Study Group Metabolic syndrome in type 1 diabetes. Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-20240.
27. West J, Brousil J, Gazis A, Jackson L, Mansell P, Bennett A et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes. Q J Med 2009; 9: 871-876.
28. Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med 2009; 26: 1235-1241.
29. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008; 31: 165-169.
30. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
31. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-1029.
32. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21: 406-412.